Yang R, et al. - Via this retrospective study, HIV/HBV-coinfected patients receiving long term lamivudine or both tenofovir and lamivudine containing therapies were examined for HBsAg seroclearance and for predictors of HBsAg loss. Among 268 HIV/HBV-coinfected patients who started treatment between 2005 and 2017, 10 (3.7%) patients showed HBsAg loss and seven (2.6%) patients, on quantification of HBsAg, had less than 50IU/mL, over a median of 65.63 months of follow-up. A tendency for a gradual increase in the rates of HBsAg seroclearance was observed with the prolongation of anti-retroviral therapy duration time; this rose from 1.8%(3/163) during 2-4 years of treatment to 29.4% (10/34) after ART for up to 10 years. Chinese individuals with HIV/HBV co-infection who have been treated with anti-HBV containing antiretroviral therapy rarely display the event of HBsAg seroclearance, and HIV/HBV co-infected patients require lifelong therapy for HBV. These findings suggest the predictive value of baseline qHBsAg and HBV-DNA levels and qHBsAg decline rate for HBsAg seroclearance.